vs
Pacira BioSciences, Inc.（PCRX）与世纪互联（VNET）财务数据对比。点击上方公司名可切换其他公司
世纪互联的季度营收约是Pacira BioSciences, Inc.的2.0倍（$362.7M vs $177.4M），Pacira BioSciences, Inc.净利率更高（1.6% vs -10.7%，领先12.3%），过去两年世纪互联的营收复合增速更高（17.4% vs -0.2%）
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
VNET Group即世纪互联，是中国领先的第三方中立数据中心服务商，提供机柜托管、云基础设施、混合云部署及网络管理等解决方案，服务覆盖科技、金融、零售等多领域企业客户，为企业数字化运营提供稳定的算力与网络支撑。
PCRX vs VNET — 直观对比
营收规模更大
VNET
是对方的2.0倍
$177.4M
净利率更高
PCRX
高出12.3%
-10.7%
两年增速更快
VNET
近两年复合增速
-0.2%
损益表 — Q1 FY2026 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $177.4M | $362.7M |
| 净利润 | $2.9M | $-38.7M |
| 毛利率 | — | 20.9% |
| 营业利润率 | 3.9% | 0.5% |
| 净利率 | 1.6% | -10.7% |
| 营收同比 | 5.0% | — |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.07 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PCRXVNET
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | — | ||
| Q3 25 | $179.5M | $362.7M | ||
| Q2 25 | $181.1M | — | ||
| Q1 25 | $168.9M | $309.5M | ||
| Q4 24 | $187.3M | — | ||
| Q3 24 | $168.6M | $302.2M | ||
| Q2 24 | $178.0M | $274.4M |
净利润PCRXVNET
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $5.4M | $-38.7M | ||
| Q2 25 | $-4.8M | — | ||
| Q1 25 | $4.8M | $-2.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-143.5M | $-2.1M | ||
| Q2 24 | $18.9M | $-1.1M |
毛利率PCRXVNET
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | — | ||
| Q3 25 | 80.9% | 20.9% | ||
| Q2 25 | 77.4% | — | ||
| Q1 25 | 79.7% | 25.2% | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 76.9% | 23.2% | ||
| Q2 24 | 75.1% | 21.3% |
营业利润率PCRXVNET
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | — | ||
| Q3 25 | 3.5% | 0.5% | ||
| Q2 25 | 4.7% | — | ||
| Q1 25 | 1.2% | 0.1% | ||
| Q4 24 | 13.2% | — | ||
| Q3 24 | -82.8% | 24.5% | ||
| Q2 24 | 15.9% | 0.2% |
净利率PCRXVNET
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 3.0% | -10.7% | ||
| Q2 25 | -2.7% | — | ||
| Q1 25 | 2.8% | -0.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | -85.1% | -0.7% | ||
| Q2 24 | 10.6% | -0.4% |
每股收益（稀释后）PCRXVNET
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | — | ||
| Q3 25 | $0.12 | — | ||
| Q2 25 | $-0.11 | — | ||
| Q1 25 | $0.10 | — | ||
| Q4 24 | $0.38 | — | ||
| Q3 24 | $-3.11 | — | ||
| Q2 24 | $0.39 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $144.3M | $492.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $653.9M | $890.8M |
| 总资产 | $1.2B | $6.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PCRXVNET
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | — | ||
| Q3 25 | $246.3M | $492.1M | ||
| Q2 25 | $445.9M | — | ||
| Q1 25 | $493.6M | $544.3M | ||
| Q4 24 | $484.6M | — | ||
| Q3 24 | $453.8M | $219.5M | ||
| Q2 24 | $404.2M | $247.2M |
总债务PCRXVNET
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | — | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | — | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | — |
股东权益PCRXVNET
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | — | ||
| Q3 25 | $727.2M | $890.8M | ||
| Q2 25 | $757.8M | — | ||
| Q1 25 | $798.5M | $927.8M | ||
| Q4 24 | $778.3M | — | ||
| Q3 24 | $749.6M | $902.9M | ||
| Q2 24 | $879.3M | $900.6M |
总资产PCRXVNET
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.3B | $6.1B | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.6B | $5.4B | ||
| Q4 24 | $1.6B | — | ||
| Q3 24 | $1.5B | $4.3B | ||
| Q2 24 | $1.6B | $4.0B |
负债/权益比PCRXVNET
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | 1.28× | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $113.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-193.1M |
| 自由现金流率自由现金流/营收 | — | -53.2% |
| 资本支出强度资本支出/营收 | — | 84.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-589.7M |
8季度趋势，按日历期对齐
经营现金流PCRXVNET
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | — | ||
| Q3 25 | $60.8M | $113.8M | ||
| Q2 25 | $12.0M | — | ||
| Q1 25 | $35.5M | $27.0M | ||
| Q4 24 | $33.1M | — | ||
| Q3 24 | $53.9M | $108.3M | ||
| Q2 24 | $53.2M | $55.8M |
自由现金流PCRXVNET
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | — | ||
| Q3 25 | $57.0M | $-193.1M | ||
| Q2 25 | $9.3M | — | ||
| Q1 25 | $26.9M | $-220.0M | ||
| Q4 24 | $31.0M | — | ||
| Q3 24 | $49.8M | $-95.0M | ||
| Q2 24 | $51.6M | $-81.6M |
自由现金流率PCRXVNET
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | — | ||
| Q3 25 | 31.7% | -53.2% | ||
| Q2 25 | 5.1% | — | ||
| Q1 25 | 15.9% | -71.1% | ||
| Q4 24 | 16.6% | — | ||
| Q3 24 | 29.6% | -31.4% | ||
| Q2 24 | 29.0% | -29.8% |
资本支出强度PCRXVNET
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | — | ||
| Q3 25 | 2.2% | 84.6% | ||
| Q2 25 | 1.5% | — | ||
| Q1 25 | 5.1% | 79.8% | ||
| Q4 24 | 1.1% | — | ||
| Q3 24 | 2.4% | 67.3% | ||
| Q2 24 | 0.9% | 50.1% |
现金转化率PCRXVNET
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 11.20× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 7.37× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.82× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
VNET
暂无分部数据
